四州卫生官员致信疾控中心：要求重新考虑验证高通量麻疹检测，称拒绝将削弱疫情应对
美国华盛顿讯：加利福尼亚州、夏威夷州、俄勒冈州与华盛顿州四州卫生官员近日联名致信疾控中心（CDC）主任 Erica Schwartz，要求该机构重新考虑拒绝验证一种高通量麻疹检测方法的决定，并为该检测制定可供各州实验室使用的方案。（GSM 据《卫报》与《纽约时报》报道）
据信件内容，加州与华盛顿州卫生官员今年5月正式请求 CDC 验证一种新的麻疹检测方法，等候两个月后，CDC 以「有其他相互竞争的优先事项」为由拒绝，表示无法投入时间把高通量检测提供给各州实验室。四州官员在信中写道：「如果本地区暴发大规模疫情，没有高通量检测能力，将更难适当地扩大诊断检测规模，从而损害患者护理与公共卫生调查。」官员们表示，这样一种检测将「显著增强」实验室快速应对疫情的能力，也有助于为埃博拉、汉坦病毒等其他已知病原体及新发威胁做准备。
目前，各州公共卫生实验室检测麻疹主要依靠通量较低的单个 PCR 检测。新冠疫情期间，多数公共卫生实验室购入了高通量设备，例如 Hologic 公司的 Panther Fusion 平台，八小时可处理多达500份检测；但迄今没有一种高通量麻疹检测方法经 CDC 发表或验证。信件还提到，德克萨斯州实验室在去年该州西部疫情期间自行开发了高通量麻疹检测，但其方案从未对外分发或发表；CDC 据报曾研究德州的检测与 ARUP Laboratories 的一种检测，但四州官员称这些研究「并非完整的验证，也不是全面的比较」。四州联盟要求 CDC 为 Panther Fusion 平台开发检测方法并公布方案，使任何实验室都能运行。
卫生与公众服务部（HHS）发言人 Emily Hilliard 回应称，CDC 正在「确保州与地方卫生部门获得所需支持，以加强麻疹检测与疫情应对」，并在为应对当前麻疹疫情「优先推进新兴技术」。她没有回答 CDC 是否计划验证高通量麻疹检测的问题。Schwartz 于今年8月就任 CDC 主任，四州官员是在收到 CDC 回复后不久向她发出此信的。
关联：跟进：CDC确认2026年第三例麻疹相关死亡 全美确诊病例维持4,410例
Four States Urge CDC to Reconsider Validating High-Volume Measles Test, Warning Refusal Weakens Outbreak Response
Washington: Health officials from California, Hawaii, Oregon and Washington have written jointly to Erica Schwartz, director of the Centers for Disease Control and Prevention (CDC), asking the agency to reconsider its refusal to validate a high-throughput measles testing method and to develop an assay that state laboratories can use. (GSM, based on reporting by The Guardian and The New York Times)
According to the letter, health officials in California and Washington formally asked the CDC in May to validate a new way of testing for measles. After waiting two months, the CDC denied the request, citing “other competing priorities” and saying it could not dedicate time to making a high-volume test available to state laboratories. “If a large outbreak were to occur in our region, without high-throughput capacity, it would be more difficult to scale up diagnostic testing appropriately, impairing patient care and public health investigation,” the officials wrote. Such a test, they said, would “dramatically strengthen” laboratories' ability to respond quickly to outbreaks and would also help preparedness for known pathogens such as Ebola and hantavirus, as well as emerging threats.
Public health laboratories currently rely on lower-volume individual PCR tests for measles. During the Covid-19 pandemic, most public health labs bought high-throughput equipment such as Hologic's Panther Fusion platform, which can process up to 500 tests in eight hours, but no high-throughput measles test has been published or validated by the CDC. The letter also noted that Texas state laboratories developed their own high-volume measles test during an outbreak in west Texas last year, but the protocol has not been distributed or published. The CDC has reportedly studied the Texas test and one from ARUP Laboratories, but the four states' officials said those studies “were not full validations or a comprehensive comparison.” The alliance is asking the CDC to develop an assay for the Panther Fusion and publish the protocol so any laboratory can run it.
Emily Hilliard, a spokesperson for the U.S. Department of Health and Human Services (HHS), said the CDC is “ensuring state and local health departments have the support needed to strengthen measles detection and outbreak response” and is “prioritizing emerging technologies” to respond to the current measles outbreak. She did not answer whether the agency plans to validate a high-throughput measles assay. Schwartz took up the CDC directorship in August, shortly after the states received the agency's reply.
发布：GSM·美国（发布链接）
图片来源：图：位于Atlanta的疾控中心CDC Roybal园区17号楼（资料图）。美国疾控中心公共领域图片，经维基共享资源。Photo: CDC Building 17 at the Roybal Campus in Atlanta (file photo). U.S. Centers for Disease Control and Prevention, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
